Stoky
Back to explore
N
NoahListening
A
AshListening
0:00 / 0:00I. Overall Revenue and Sales Performance
BDX logo

Becton Dickinson Reports Q2 2026 Resilience Driven by Organic Growth and Surgical Procedure Volume

BDX8-KFiling Date: 5/7/2026
Becton, Dickinson and Company
Description

What this story covers

Noah and Ash discuss Becton Dickinson’s Q2 2026 results, highlighting strong organic revenue growth across Medical and Interventional segments. The analysis covers how BD utilized automation and strategic pricing to maintain profitability despite global inflationary pressures and supply chain challenges.

Story snapshot

CompanyBecton, Dickinson and Company
TickerBDX
VariantStandard detailed
Duration6:07
Filing type8-K
PeriodQ2 2026
IndustryHealthcare & Pharmaceuticals
Accession0001628280-26-031638
Sources1

Full Story Script

Content not available for this story.

Primary Sources

sec_filing8-KView on SEC.gov →

Ask Noah

Question the story, source filings, and key financial signals.

Sign in to chat with Noah

Ask questions about revenue, margins, risk factors, filings and more. Noah uses retrieval-augmented analysis over raw financial disclosures.

Sign in